BACKGROUND AND OBJECTIVES
The RSVpreF vaccine, licensed for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease in infants <6 months via maternal immunization, protects infants through transplacental-transferred antibodies. Additional benefits may be conferred via vaccine-indu...
Jessica E. Atwell, J. Deese, Mayte Suarez-Farinas et al.· Breastfeeding Medicine· 0 citations
INTRODUCTION
Respiratory syncytial virus (RSV) and influenza cause substantial acute respiratory illness (ARI) and may be difficult to distinguish clinically. We compared characteristics of adults hospitalized with ARI, diagnosed with RSV versus influenza, using standardized systematic testing.
METHODS
The North Amer...
N. Aliabadi, Hammad Ali, Qing Liu et al.· Infectious Disease and Thera...· 0 citations
BACKGROUND
Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...
M. Lassen, S. Christensen, M. Yafasov et al.· NEJM Evidence· 1 citation
Precision of VE against RSV-related ARI ED/hospital admissions improved substantially with inclusion of salvage testing compared to SOC testing alone, suggesting that frequent standard-of-care RSV testing contributes to underestimated disease burden.
B. Ackerson, Brandon Chia, N. Aliabadi et al.· Open Forum Infectious Diseas...· 0 citations
In adults aged 60 years or older, RSVpreF vaccination reduced hospitalisations for RSV-related respiratory tract disease with no statistical evidence of effect modification by immunosuppression status; however, the study was not powered to exclude subgroup differences.
A. Reimer Jensen, M. H. Højbjerg Lassen, N. Johansen et al.· The Lancet Healthy Longevity· 0 citations
BACKGROUND
Although evidence suggests some direct protection against Streptococcus pneumoniae serotype 3 (Spn3) from the 13-valent pneumococcal conjugate vaccine (PCV13), Spn3 remains a common cause of pneumococcal disease. We aimed to assess whether serotype-specific humoral immune responses to capsule polysaccharide...
P. Gonzalez-Dias, A. Gonçalves, J. Reiné et al.· The Lancet Microbe· 0 citations
The meta-analysis provides robust estimates for use in decision-analytical models designed to predict the impact of Hib vaccine, and provides robust estimates for use in decision-analytical models designed to predict the impact of Hib vaccine.
U. Griffiths, A. Clark, B. Gessner et al.· 0 citations
Regression analyses showed that there was a 2·5-times increase in the odds of vaccinated children having increased pneumococcal density 14 days later, compared with that in unvaccinated children, and a 2·0-times increase in the odds of S pneumoniae acquisition in household members after administering LAIV.
J. Metz, George Qian, B. Morales-Aza et al.· The Lancet Microbe· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.